Our understanding of the coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has improved greatly since the first human cases were reported in December 2019 in Wuhan City, China1,2. COVID-19 is known to involve multiple organ systems, with the major disease burden resulting from respiratory, cardiovascular, thrombotic and neurological complications3–5. Cellular entry of SARS-CoV-2 depends on binding of the viral spike (S) protein to cellular receptors such as angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed in multiple organ systems6,7, and on S-protein priming by host-cell proteases8,9. In some individuals these steps are followed by a cascade of inflammatory events, resulting in a ‘cytokine storm’. This massive pro-inflammatory cellular and cytokine response is a feature of patients with severe COVID-19 disease10.

Although morbidity and mortality from primary COVID-19 infection have remained limited in children, we have witnessed the emergence of a new inflammatory disorder associated with COVID-19, termed multisystem inflammatory syndrome in children (MIS-C) in the USA and paediatric inflammatory multisystemic syndrome (PIMS) in Europe11–15. Current evidence suggests that MIS-C is a post-infectious, immunologically mediated disorder related to prior SARS-CoV-2 exposure. Epidemiological, clinical and immunological differences classify MIS-C as being distinct from Kawasaki disease. Differences include the age range, and the geographical and ethnic distribution of patients. MIS-C is associated with prominent gastrointestinal and cardiovascular system involvement, admission to intensive care unit, neutrophilia, lymphopenia, high levels of IFNγ and low counts of naive CD4+ T cells, with a high proportion of activated memory T cells. Further investigation of MIS-C will continue to enhance our understanding of similar conditions associated with a cytokine storm.

Overview of Kawasaki disease

Kawasaki disease is a paediatric, self-limited, systemic inflammatory vasculitis that was first described in 1967 in Japan by Dr Tomisaku Kawasaki19. The most important long-term sequelae of Kawasaki disease relate to abnormalities of the coronary artery, and it is now the
Key points

- Multisystem inflammatory syndrome in children (MIS-C) is characterized by exaggerated innate and adaptive immune responses following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in predisposed children.
- Clinical presentation of MIS-C involves multiple organ systems, with prominent involvement of the gastrointestinal and cardiovascular systems.
- The factors that trigger the development of MIS-C in children exposed to or infected with SARS-CoV-2 are not yet known.
- Results from epidemiological, clinical and immunological investigations have revealed that although MIS-C has phenotypic similarities to Kawasaki disease, they are different syndromes.
- The approach to treatment of MIS-C aims to mute the augmented inflammatory response.

most common cause of acquired heart disease in children in the developed world. A diagnostic feature of Kawasaki disease is fever that persists for more than 5 days when untreated. Additional typical clinical features include polymorphic skin rash (erythema), involvement of lips and oral mucosa (lip fissures, strawberry tongue), lymphadenopathy (cervical, often unilateral), non-exudative bilateral conjunctivitis and extremity changes (erythema and oedema of palms and soles that desquamate after 2–3 weeks, usually seen in the subacute phase).

Aetiology

The aetiology of Kawasaki disease is uncertain, and there is no single specific diagnostic test. The general consensus, based on results from multiple studies, is that Kawasaki disease is an immune-mediated disease triggered by infection (or infections) in patients with a genetic predisposition. Some epidemiological features offer clues to the pathogenesis of Kawasaki disease. It is typically noted in children between the ages of 6 months and 5 years, with an estimated incidence of 25 cases per 100,000 children younger than 5 years in North America. It is believed that children younger than 6 months, who have immature immune systems, are protected by passive immunity provided by the transplacental transfer of maternal antibodies, whereas children older than 5 years have developed protective antibody responses to the ubiquitous antigens that most encounter unevenly in early childhood. There is a male predominance (~1.5:1) in the incidence of Kawasaki disease, a feature that is shared by many common childhood infectious diseases.

Seasonal variation in the incidence of Kawasaki disease has been noted, with peak incidence occurring in winter and spring in the USA and UK, and in summer in China and Korea. Seasonal variation is least evident in Japan, the country with the highest incidence of Kawasaki disease. Geographical variation and clustering in the incidence of Kawasaki disease also occurs, with the highest incidence reported in Japan, China, South Korea and Taiwan. These epidemiological features point towards a transmissible infectious agent, which tends to occur in certain regions of the world with a seasonal variation in its incidence. Evidence exists for the presence of concurrent infections (with bacteria or common respiratory viruses, including coronaviruses) in patients with Kawasaki disease.

Involvement of superantigens

The potential pathogenic role of superantigens has been evaluated, on the basis of observations of preferential expression of T cell receptor (TCR) β genes encoding variable regions Vβ2 and Vβ8.1 in the peripheral blood lymphocytes of patients with acute Kawasaki disease. Superantigen activity has been identified in the gut microbiota of such patients, and culture supernatants of these bacteria contain a heat shock protein (Hsp60, also known as GroEL) that induces T cell division and production of pro-inflammatory cytokines. However, in studies using flow cytometry in large series of patients with Kawasaki disease, TCR skewing and over-presentation of the described TCR clones has not been found, and it is currently believed that Kawasaki disease is a result of T cell activation by a conventional antigen.

Involvement of nutritional disorders

The role of nutritional disorders, including vitamin D deficiency, in the pathogenesis of Kawasaki disease is subject to debate. Vitamin D has an anti-inflammatory effect mediated through elevation of expression of IL-10 and inhibition of expression of vascular endothelial growth factor. Results from a German population-based study showed that vitamin D supplementation has a protective effect against the development of Kawasaki disease. Low serum concentrations of vitamin D might contribute to the development of coronary artery complications in children with Kawasaki disease. However, other results have
Dysbiosis is associated with reduction in the production of short-chain fatty acids (particularly butyrate) and is proposed to lead to aberrant immune responses that are associated with Kawasaki disease.

**Genetic susceptibility**

Epidemiological and genetic studies of Kawasaki disease have shed light on the role of genetic susceptibility in its development. Kawasaki disease is prevalent in Japan, but also in children of Japanese ancestry living in Hawaii. Siblings of children with Kawasaki disease have a 10-fold higher risk of development of the condition than children in the general population. Several candidate genes have been identified through genome-wide association studies and linkage studies. The four major groups of genes that have been studied in Kawasaki disease are those associated with T cell activation (ORAI1 and STIM1), B cell signalling (CD40, BLK and FCGR2A), apoptosis (CASP3) and transforming growth factor-β (TGFβ) signalling (TGFβ2, TGFβR2, MMP and SMAD). CASP3 encodes caspase 3, which is an effector caspase with a vital role in the execution phase of apoptosis. A single-nucleotide polymorphism in the CASP3 gene is associated with susceptibility to Kawasaki disease. TGFβ is another vital protein with a central role in immunoregulation that affects multiple populations of leukocytes. Abnormalities in TGFβ signalling resulting from genetic variation are involved in Kawasaki disease susceptibility and outcomes.

Understanding the roles of these genetic alterations has implications for potential therapeutic approaches. In addition to these groups, mutations in ITPKC, which is involved in Ca2+ mobilization and activation of NLRP3 inflammasomes, could result in enhancement of IL-1β and IL-18 production, disease susceptibility, coronary abnormalities and resistance to treatment with intravenous immunoglobulin (IVIG). Notably, immunosuppressive agents such as ciclosporin, a T cell inhibitor that blocks the calcineurin–NFAT pathway, have shown promise in the treatment of high-risk IVIG-resistant Kawasaki disease. The observed association of HLA polymorphisms with Kawasaki disease varies; the predominant variant in a Japanese cohort was HLA-Bw54, whereas HLA-Bw51 was predominantly identified in white and Jewish populations. Epigenetic regulation of inflammatory and immunoregulatory genes by factors such as methylation, microRNAs and long non-coding RNAs has been identified in Kawasaki disease, and might be relevant to pathogenesis and prognosis. Additionally, single-nucleotide polymorphisms in cytokine genes, including IL1, KCNN2, TIFAB, P2RY12 and TNF, are associated with Kawasaki disease and with risk of coronary artery lesions, as well as IVIG treatment failure.

**Immunological aberrations**

Innate and adaptive immune responses both have important roles in the development of Kawasaki disease. An intense initial response driven by the innate immune system takes the form of neutrophilic leukocytosis, activation of monocytes, natural killer (NK) cells and γδ T cells, and elevation of production of acute-phase proteins. Dysbiosis is associated with reduction in the production of short-chain fatty acids (particularly butyrate) and is proposed to lead to aberrant immune responses that are associated with Kawasaki disease.

### Table 1 | Comparison of Kawasaki disease and MIS-C

| Demographics | Kawasaki disease | MIS-C |
|--------------|-----------------|-------|
| Age          | 6 months to 5 years | 6–11 years |
| Sex          | Male predominance (~5:1) | No apparent predominance |
| Race or ethnicity | Highest incidence in Japan, China, South Korea and Taiwan | Highest incidence in children of African and Hispanic heritage |

**Pathogenesis**

| Trigger | Unknown but some data suggest possible preceding viral or bacterial infection | Onset ~3–6 weeks after SARS-CoV-2 exposure |

**Immunological characteristics**

| Similarities | Enhancement of IL-1β+ neutrophils and immature neutrophils |
| Differences | T cell activation by a conventional antigen |
| Cytokine profile | SARS-CoV-2 viral spike (S) protein acts like a superantigen, triggering a cytokine storm |
| High levels of IL-17 | High levels of IL-15, IFNγ in severe cases |
| Relatively less frequent MAS-like cytokine profile | >50% of patients with MIS-C have a MAS-like cytokine phenotype |
| Lymphopenia is rare | Lymphopenia |
| Anti-SARS-CoV-2 IgG not reported | Anti-SARS-CoV-2 IgG |

**Clinical features**

| Similarities | Similar associations with fever, rash, cervical lymphadenopathy, neurological symptoms, extremity changes |
| Differences | Relatively high incidence of conjunctival injection and oral mucous membrane changes |
| Cytokine profile | Relatively high incidence of gastrointestinal symptoms, myocarditis and shock, and coagulopathy |

**Management**

| Common | IVIG, glucocorticoids, acetylsalicylic acid |
| Rare | Infliximab, ciclosporin and anakinra |

IVIG, intravenous immunoglobulin; MAS, macrophage activation syndrome; MIS-C, multisystem inflammatory syndrome in children; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
reactants and cytokines, especially IL-1β, which contributes to activation of endothelial cells, inducing upregulation of expression of cell-adhesion molecules, IL-6 and IL-8. Pro-inflammatory IL-17 produced by type 17 T helper (T_{h17}) cells could activate immune cells such as neutrophils and monocytes, leading to production of other inflammatory cytokines, such as IL-6, TNF and IL-8, thereby contributing to the pathogenesis of many inflammatory disorders. By contrast, CD4+CD25+ regulatory T (T_{reg}) cells contribute to immune tolerance through suppression of the hyperactivation of both innate and adaptive immune cells, via several mutually nonexclusive mechanisms. An imbalance in these pathways could lead to immune dysregulation, which could have a role in the pathogenesis of Kawasaki disease.

Neutrophils are activated in Kawasaki disease and release reactive oxygen species, leading to endothelial cell injury. Release of neutrophil extracellular traps (NETs) is also implicated in the pathogenesis of Kawasaki disease. Although NETs have a protective role against infections as components of the innate immune system, they also have pathogenic potential for immune dysregulation and promotion of inflammation and tissue injury. NETs have been implicated in the development and progression of rheumatic diseases, including systemic lupus erythematosus, rheumatoid arthritis and autoimmune vasculitis. Yoshida et al. demonstrated elevation of NET formation in the sera of patients with Kawasaki disease, as well as neutrophil infiltration in the lesions of vasculitis in the coronary arteries and aorta in a mouse model of Kawasaki disease.

Autoimmune antibodies are thought to have a role in the pathogenesis of Kawasaki disease, particularly those against endothelial cell antigens. Anti-endothelial cell antibodies could cause endothelial damage, with release of pro-inflammatory cytokines and a hypercoagulable state leading to vessel-wall injury and intravascular thrombosis. However, not all results have demonstrated elevation of anti-endothelial cell antibodies in patients with Kawasaki disease.

Immune complexes might have a role in the development of Kawasaki disease. They appear in the first 7 days of the disease and peak in the second week before declining. Elevation of circulating levels of immune complexes in Kawasaki disease is related to adverse outcomes such as coronary artery abnormalities. However, a causal relationship between immune complexes and the pathogenesis of Kawasaki disease has not been definitively established. Activation of the complement system has also been implicated in the pathogenesis of Kawasaki disease, via both the classical and the mannose-binding lectin pathways.

Kawasaki disease is considered by some to be a form of IgA vasculitis. In children with Kawasaki disease, intestinal permeability and levels of secretory IgA in the circulation are greater than in unaffected children, and in mouse models of the disease, elevation of levels of circulating secretory IgA and IgA deposition in the vasculature are observed. Furthermore, pharmacological blockade of zonulin (a modulator of intestinal tight junctions) and administration of IVIG in these mouse models reduce intestinal permeability and cardiovascular inflammation compared with levels in untreated controls.

Therapeutic strategies

IVIG and acetylsalicylic acid have emerged as first-line therapies for the management of Kawasaki disease. IVIG therapy leads to rapid improvement in the clinical symptoms of rash, fever and conjunctival injection in most patients. Although the exact mechanism of action of IVIG is not yet known, proposals include inhibition of activation of innate immune cells and inflammatory mediators, expansion of T_{reg} cells and suppression of T_{h17} cells. Evidence indicates that IVIG might target IL-1β+ neutrophils via caspase-independent pathways. Single-cell RNA sequencing of peripheral blood mononuclear cells in acute Kawasaki disease before and after IVIG therapy has revealed that genes encoding inflammatory mediators (including TNF and IL1B) are highly expressed in monocytes in untreated disease, with reduction of expression following therapy, along with significant enhancement of the plasma-cell population and induction of oligoclonal expansion of T cell receptors and IgG and IgA B cell receptors. Mining of transcriptomic data by Boolean analysis has identified that several metabolic pathways might contribute to IVIG resistance in Kawasaki disease.

In high-risk patients with acute Kawasaki disease and in those who do not respond to IVIG therapy, steroid treatment can be considered, to prevent the occurrence of coronary artery abnormalities. Additional therapeutic options for IVIG-resistant Kawasaki disease include infliximab (a monoclonal antibody to TNF), ciclosporin (a calcineurin inhibitor) and anakinra (an IL-1 receptor antagonist).

Overview of MIS-C

Since April 2020, many reports have documented a new hyperinflammatory syndrome in children. In May 2020, the US Centers for Disease Control and Prevention (CDC) issued an alert identifying MIS-C as a critical illness in children that was associated with SARS-CoV-2 infection. Since then, more than 4,000 cases of MIS-C have been reported in the USA alone. In 26 studies published in 2020 and 2021, documenting 1,136 cases of MIS-C (mostly occurring in the USA and Europe), the reported median ages of the affected children were 6–11 years, with no significant gender difference. MIS-C patients with MIS-C have symptoms that resemble those of other hyperinflammatory syndromes, such as Kawasaki disease, toxic-shock syndrome (TSS) and macrophage activation syndrome (MAS), which is a type of secondary haemophagocytic lymphohistiocytosis. To improve clarity and aid diagnosis, the CDC published a case definition, which includes age <21 years, fever, laboratory evidence of inflammation, hospital admission, multisystem (two or more) organ involvement (cardiac, renal, respiratory, haematological, gastrointestinal, dermatological or neurological), either laboratory confirmation of SARS-CoV-2 infection (by PCR with reverse transcription (RT–PCR), serology or antigen test) or known COVID-19 exposure up to 4 weeks.
before symptom onset, with no alternative plausible diagnosis. The WHO and the UK Royal College of Paediatrics and Child Health (RCPCH) have also published case definitions, which are largely similar to the CDC definition, except that the RCPCH does not require evidence of prior exposure to SARS-CoV-2 (refs \[141,142\]).

Despite the broad case definitions, and the considerable overlap with primary COVID-19 and other common childhood febrile illnesses, patients with MIS-C have distinct clinical presentation and levels of biomarkers, which aids in differential diagnosis.\[143–145\].

### Aetiology

Compared with adults, primary SARS-CoV-2 infection is relatively mild in children.\[146\]. Evidence indicates that a temporal relationship exists between SARS-CoV-2 infection and the development of MIS-C.\[147\]. The exact mechanisms underlying the development of MIS-C are not fully understood, but it is thought to be an inflammatory response to SARS-CoV-2 infection, leading to the activation of monocytes, macrophages, and T cells.\[148\].

### Table 2 | Demographic features of MIS-C study populations

| Study                  | Cohort location | N       | Median age, years (range or IQR) | Male:female (%) | Race or ethnicity                                      | Ref. |
|------------------------|-----------------|---------|-----------------------------------|-----------------|--------------------------------------------------------|------|
| Dufort et al.          | USA             | 99      | No median Distribution: 0–5, 31%; 6–12, 42%; 13–20, 26% | 54:46           | Black, 40%; white, 37%; Hispanic, 36%; other, 18%; Asian, 5% | 14   |
| Cheung et al.          | USA             | 17      | 8 (1.8–16)                        | 47:53           | Ashkenazi Jewish, 35%; Black, 24%; Hispanic, 24%; white non-Hispanic, 12%; Asian, 6% | 15   |
| Belhadjer et al.       | France, Switzerland | 35     | 10 (2–16)                         | 51:49           | Not reported                                           | 122  |
| Kaushik et al.         | USA             | 33      | 10 (IQR 6–13)                     | 61:39           | Hispanic, 45%; Black, 38%; white, 9%; Asian, 3%; other, 3% | 125  |
| Davies et al.          | UK              | 78      | 11 (IQR 8–14)                     | 67:33           | Afro-Caribbean, 47%; Asian, 28%; white, 22%; other, 3% | 126  |
| Pouletty et al.        | France          | 16      | 10 (IQR 4.7–12.5)                 | 50:50           | Not reported                                           | 127  |
| Toubiana et al.        | France          | 21      | 7.9 (3.7–16.6)                    | 43:57           | Sub-Saharan African/Caribbean parentage, 57%; European parentage, 29%; Asian parentage, 10%; Middle Eastern parentage, 5% | 128  |
| Capone et al.          | USA             | 33      | 8.6 (IQR 4.4–12.6)                | 61:39           | Other, 45%; Black, 24%; Asian, 9%; white, 9%; unknown, 12% (Hispanic, 27%; non-Hispanic, 73%) | 129  |
| Hameed et al.          | UK              | 35      | 11 (IQR 6–14)                     | 77:23           | Not reported                                           | 130  |
| Whittaker et al.       | UK              | 58      | 9 (IQR 5.7–14)                    | 56:44           | Black, 38%; Asian, 31%; white, 21%; other, 10%         | 131  |
| Morelleda et al.       | Spain           | 31      | 7.6 (IQR 4.5–11.5)                | 58:42           | Not reported                                           | 132  |
| Dhanalakshmi et al.    | India           | 19      | 6 (1.1–16.9)                      | 42:58           | Not reported                                           | 133  |
| Miller et al.          | USA             | 44      | 7.3 (0.7–20)                      | 45:55           | Hispanic, 34%; not reported, 25%; white, 20.5%; Black, 20.5% | 134  |
| Belot et al.           | France          | 108     | 8 (IQR 5–11)                      | 49:51           | Not reported                                           | 135  |
| Lee et al.             | USA             | 28      | 9 (0.1–17)                        | 57:43           | Hispanic, 43%; white, 36%; Black, 18%; not reported, 3% | 136  |
| Riollano-Cruz et al.   | USA             | 15      | No median Mean 12 (3–20)          | 73:27           | Hispanic, 66%; non-Hispanic African American, 13%; non-Hispanic white, 13%; other, 8% | 137  |
| Ramcharan et al.       | UK              | 15      | 8.8 (IQR 6.4–11.2)                | 73:27           | African or Afro-Caribbean, 40%; South Asian, 40%; mixed, 13%; other, 7% | 138  |
| Grimaud et al.         | France          | 20      | 10 (2–16)                         | 50:50           | Not reported                                           | 139  |
| Perez-Toledo et al.    | UK              | 8       | 9 (7–14)                          | 63:37           | Not reported                                           | 140  |
| Jonat et al.           | USA             | 54      | 7 (0.7–20)                        | 46:54           | White, 35%; unknown, 31%; other, 19%; African American, 15% | 141  |
| Feldstein et al.       | USA             | 186     | 8.3 (IQR 3.3–12.5)                | 65:35           | Hispanic, 31%; Black, 25%; unknown, 22%; white, 19%; other, 5% | 13  |
| Toubiana et al.        | France          | 23      | 8.2                               | 52:48           | Not reported                                           | 136  |
| Garcia-Salido et al.   | Spain           | 61      | 9.4 (IQR 5.5–11.8)                | 66:34           | Not reported                                           | 145  |
| Shobhavat et al.       | India           | 21      | 7 (IQR 1.9–12.1)                  | 47:53           | Not reported                                           | 146  |
| Niño-Taravilla et al.  | Chile           | 26      | 6.5 (IQR 2–10.5)                  | 58:42           | Chilean, 73%; Venezuelan, 12%; Peruvian, 8%; Colombian, 4%; Haitian, 4% | 142  |
| Toulany et al.         | Turkey          | 52      | 9 (IQR 5–13)                      | 38:62           | Turkish, 86%; Syrian, 14%                             | 143  |

IQR, interquartile range; MIS-C, multisystem inflammatory syndrome in children.
Reviews for the development of MIS-C has yet to be firmly established.

IgG response. It should be noted that implication of SARS-CoV-2 as a triggering factor in MIS-C is associated with a strong anti-spike protein IgG response, but a weak IgM response. It should be noted that implication of SARS-CoV-2 as a triggering factor for the development of MIS-C has yet to be firmly established.

Fig. 1 | The temporal relationship between SARS-CoV-2 infection and development of MIS-C. Evidence suggests that a relationship exists between the timing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and development of multisystem inflammatory syndrome in children (MIS-C). Cases of MIS-C tend to be seen 3–6 weeks after the peak of SARS-CoV-2 transmission in a community. Because of this time lag, MIS-C is associated with a strong anti-spike protein IgG response, but a weak IgM response. It should be noted that implication of SARS-CoV-2 as a triggering factor for the development of MIS-C has yet to be firmly established.

SARS-CoV-2 with respect to specificity and isotype distribution (including IgG, IgM and IgA isotypes) and higher virus-neutralizing capacity. The mild or asymptomatic nature of COVID-19 in children might be related to the extent of the antibody response. Nevertheless, IgG antibodies to S protein provide an important diagnostic criterion for MIS-C. Low IgM titres in MIS-C are consistent with its appearance several weeks after SARS-CoV-2 exposure.

Analyses from geographically diverse cohorts have demonstrated that 20–50% of people with no previous exposure to the virus have T cell reactivity against peptides corresponding to SARS-CoV-2 sequences, which might be related to CD4+ T cell cross-reactivity with circulating seasonal human ‘common cold’ coronavirus (HCoV). Although this phenomenon has implications for the development of herd-immunity models and vaccine candidates, it is currently unclear whether the presence of prior cross-reactive CD4+ T cells is protective or harmful in the pathogenesis of MIS-C. When tested for serological evidence of prior seasonal coronavirus infection, children with MIS-C and those hospitalized for non-COVID reasons had similar prevalence and levels of antibodies to HCoV. Additionally, HCoV antibody levels did not correlate with the levels of SARS-CoV-2 antibodies, suggesting that prior HCoV infection neither provides protection nor worsens the course of paediatric SARS-CoV-2 infection or MIS-C.

SARS-CoV-2 S protein as a superantigen
SARS-CoV-2 viral S protein might behave like a superantigen, triggering a cytokine storm that results in the development of the TSS-like presentation of MIS-C (Fig. 2). The S protein has a high-affinity motif for binding TCR, which is similar in structure to the staphylococcal enterotoxin B, a superantigen that mediates TSS by interacting with both TCR and MHC class II molecules. Computational modelling has shown that SARS-CoV-2 encodes a superantigen motif near the S1/S2 cleavage site, which interacts with both the TCR and CD28. TCR repertoire analysis of T cells in a small number of patients with MIS-C has identified skewing of TCR Vβ towards TRBV11-2 (Vβ21.3), which is associated with HLA class I alleles A02, B35 and C04. The CDR3-independent nature of TCR Vβ skewing suggested superantigen–mediated activation of T cells in MIS-C. Further evidence supports the enrichment of TRBV11–2 among T cells, although notably it has been observed in the absence of differential expression of a set of ‘superantigen genes’. Also, MIS-C is usually observed several weeks after primary SARS-CoV-2 exposure, in contrast to the acute illness and cytokine storm observed in TSS. In most cases, SARS-CoV-2 is undetectable in patients with MIS-C during the acute phase of inflammation. Thus, the superantigenic property of SARS-CoV-2 S protein and its implication in MIS-C is not yet confirmed. As an RNA virus, SARS-CoV-2 undergoes constant mutation, and whether any particular variant of the virus contributes to MIS-C by triggering strong inflammatory signalling in the immune cells and endothelial cells of children with COVID-19 requires further exploration.
that mutations in the binding region of SARS-CoV-2 S protein could influence the interaction with MHC class II molecules and TCR\textsuperscript{165}.

**Involvement of nutritional disorders**

Nutritional factors such as vitamin D deficiency might have a role in the development of MIS-C. Adults with vitamin D deficiency were noted to have a more severe form of COVID-19 with an increased risk of death than those without this deficiency\textsuperscript{167}. Vitamin D supplementation has proved to be of some benefit in infections with other viruses, such as influenza A\textsuperscript{168}. Whether a similar benefit could accrue in MIS-C has not been elucidated.

**The role of microbiota**

Another contributing factor in the development of MIS-C that warrants investigation is the role of gut and respiratory tract microbiota. Gastrointestinal microbes are important regulators of the gut immune system and inflammation, and influence the balance between T\textsubscript{H}17 cells and T\textsubscript{reg} cells\textsuperscript{169}. Adult patients with COVID-19 display alteration of gut and upper respiratory microbiomes, and gut dysbiosis persists beyond the nasal clearance of SARS-CoV-2 (REFS\textsuperscript{170–173}). Notably, faecal SARS-CoV-2 load is inversely correlated with the abundance of bacteria of the Bacteroidetes phylum, which suppress ACE2 in the mouse gut\textsuperscript{173}. Preliminary data...
from peer reviewed and non-peer reviewed reports also suggest the persistence of microbiome dysbiosis in the upper respiratory tract and the gut in paediatric COVID-19 (REFS 174,175).

**Genetic susceptibility**

The low incidence of MIS-C relative to COVID-19, and the similarity in antibody response to SARS-CoV-2 in paediatric patients with MIS-C and with COVID-19 (irrespective of the subsequent development of MIS-C) suggest that SARS-CoV-2 infection causes dysregulation of immune responses in a subgroup of predisposed children with particular genetic backgrounds176. Specifically, predisposition might be related to mutations and polymorphisms in the genes that encode pattern recognition molecules such as Toll-like receptors, components of the signalling cascades of the immune response and Fcγ receptors (FIG. 2). The incidence of MIS-C is higher in children of African and Hispanic heritage than in those of other ethnicities, although attribution of this finding to genetic differences is confounded by the contribution of socioeconomic factors to the risks of SARS-CoV-2 infection177–180. Among 145 HLA-A, HLA-B and HLA-C genotypes, HLA-B*46:01 was associated with in silico prediction of the fewest SARS-CoV-2-binding peptides (suggesting particular vulnerability to COVID-19), whereas HLA-B*15:03 was predicted to have the greatest capacity for coronavirus peptide presentation (suggesting protective T cell-based immunity)181. Monogenic loss-of-function variants affecting immunity in the type I interferon signalling pathway might confer a predisposition to severe COVID-19 manifestations182,183. In a study of two unrelated patients with infection-associated immune thrombocytopenia and autoimmune haemolytic anaemia, both had SOCS1 haploinsufficiency and exhibited T cell activation and high levels of interferon signalling, and one developed MIS-C after SARS-CoV-2 infection. SOCS are negative regulators of interferon signalling, and silencing mutations might predispose the individuals to infection-associated hyperinflammatory states such as MIS-C184 (FIG. 2). However, a clear genetic basis that explains why some children develop MIS-C after SARS-CoV-2 exposure is currently undetermined. Additional factors, such as epigenetic effects at the level of histones, DNA or microRNA might also contribute to the development of MIS-C.

**Immunological aberrations**

In general, the signatures of immune cells and inflammatory parameters of MIS-C closely overlap with those of adults with moderate-to-severe COVID-19 rather than with paediatric COVID-19, which is mostly mild or asymptomatic. Also, immune activation in MIS-C is transient and tends to reduce during recovery154,185,186.

**Pro-inflammatory mediators.** Elevation of levels of pro-inflammatory cytokines such as IL-6, IL-10 and IL-17A, and chemokines such as CXCL5, CXCL11, CXCL1 and CXCL6 in MIS-C distinguishes it from paediatric COVID-19 (REFS 135,136,143,153). In various cohorts, elevation of TNF, IL-1β, IFNγ, soluble IL-2R, CCL2, CCL3, CCL4, CXCL8 (IL-8) or IFNγ-induced chemokines CXCL9 and CXCL10 has been reported in the serum of patients with MIS-C relative to those with paediatric COVID-19 or healthy controls134,135,187–189. Overall, enhancement of these pro-inflammatory molecules in the circulation indicates inflammatory responses of myeloid and lymphoid cells. Endothelial cells could also contribute innate inflammatory mediators, as E-selectin, a marker of inflamed endothelial cells, shows elevation in the serum of patients with MIS-C134. The reasons for the absence of some pro-inflammatory mediators in particular cohorts of patients are not known. The mediators that were analysed could have differed from study to study, but also, the levels of inflammatory mediators might vary depending on the patients’ genetic and epigenetic backgrounds, severity of the disease, geographical location and timing of the analyses. Results from a study of plasma proteomics in children with SARS-CoV-2 infection, which have not yet undergone peer review, suggest that IFNγ expression is heterogeneous among patients with MIS-C, and that patients have dysregulated response to IFNγ184. As the pandemic progresses, it will be important to have a consensus regarding the panel of cytokines and chemokines that should be analysed in relation to MIS-C, to facilitate our understanding of the molecular pathogenesis and heterogeneity of this complex disease, and to enable accurate prognosis and effective treatment.

**Immune-cell profiles.** Immune-cell profiling of children with MIS-C or primary COVID-19 infection reveals similarities as well as differences in their immune signatures185. They have similar proportions of eosinophils, immature granulocytes, monocytes and classic dendritic cells, but patients with MIS-C have elevation of neutrophils and reduction of plasmacytoid dendritic cells136,153,185,188, which might contribute to the low levels of IFNα that are observed in the blood of patients with MIS-C relative to those with paediatric COVID-19 (REF 184).

Neutrophils and monocytes are activated in patients with MIS-C185 and show upregulation of alarmin signatures (in particular S100A genes) and reduction of expression of antigen-presenting, antigen-processing and co-stimulatory molecules133,135,146,186. Compared with healthy children, those with MIS-C have greater expression of cytotoxicity genes and CCL4 in NK cells, which might contribute to the occurrence of tissue damage134. Preliminary results suggest that plasma levels of IFNγ correlate with levels of NCR1 and IL-2RA, which are the soluble markers of activated NK and T cells, respectively190.

MIS-C could have a common pathophysiology with Kawasaki disease involving NET formation, which has been described in the sera of adults with COVID-19 and with endothelial injuries or a prothrombotic state191–193. However, plasma levels of NETs and release of NETs from neutrophils are similar in children with mild or moderate COVID-19 or MIS-C and in healthy children194. Despite similarities between disorders associated with pathogenic NETs and MIS-C, the role of NETosis in the pathogenesis of MIS-C remains uncertain because of a lack of definitive evidence, and hence further studies are warranted.
Both MIS-C and paediatric COVID-19 present with general lymphopenia (affecting cells that include mucosa-associated invariant T cells, γδ T lymphocytes and CD8+ T lymphocytes). Compared with paediatric COVID-19, in MIS-C there is more-pronounced CD4+ T cell-biased lymphopenia, which is similar to the situation in severely ill adults with COVID-19. However, results from single-cell RNA sequencing analysis have revealed enhanced proliferation of CD4+ T cells in patients with MIS-C compared with healthy individuals, suggesting that lymphopenia might be the result of homing of T cells to the inflamed tissues. Despite showing T cell lymphopenia, the relative distribution of various T cell subsets such as naive, central memory and effector memory cells in patients with MIS-C is similar to that in age-matched healthy individuals, indicating a pan-CD4+/CD8+ T cell lymphopenia, rather than a subset-specific effect.

A distinct feature of MIS-C compared with paediatric COVID-19 is the activation of CXCR1+CD8+ T cells (CD8+ T cells that express vascular endothelium-homing CXCR1, also known as fractalkine receptor), which could have implications for development of vascular abnormalities and cardiovascular abnormalities. This immunological phenotype is correlated with elevation of D-dimer, reduction of platelets and with the requirement for vasoreactive medication. Although not as prominent as in NK cells, CD8+ T cells in MIS-C also show increases in signatures of cytotoxicity compared with those in healthy children. RNA sequencing in blood from children with MIS-C revealed aberrant NK and CD8+ T cell regulation, with depletion of NK cells and an absence of NK cell-dependent exhaustion of effector CD8+ T cells, which can lead to sustained inflammation. Notably, the proportion of activated CXCR1+CD8+ T cells in patients with MIS-C decreases as the clinical status improves. Thus, there seems to be a sustained activation and dysregulation of CD8+ T cells, particularly those that express CXCR1.

Non-specific activation of B cells and expansion of plasmablasts occurs in MIS-C. Plasmablast elevation also occurs in children with COVID-19. However, the specificity of expanded B cells and plasmablasts might vary between the two conditions. Patients with MIS-C display pronounced autoreactivity signatures of plasma immunoglobulins compared with healthy children or adults and children with COVID-19. Also, patients with MIS-C have evidence of extracellular responses, as indicated by high frequencies of plasmablasts expressing the T box transcription factor TBET. Future research should aim to uncover the reasons for this B cell activation, and should compare the characteristics of expanded B cells and plasmablasts, and the specificities of immunoglobulins, in MIS-C and paediatric COVID-19. As both conditions are associated with non-specific B cell activation and elevation of plasmablast frequencies, molecular mimicry between self-antigens and SARS-CoV-2 antigens (as described in a paper that has not yet been peer reviewed) might not be entirely responsible for the appearance of autoreactivity in MIS-C, and instead a combination of molecular mimicry and dysfunctional immunoregulatory machinery could be involved.

**Humoral features.** Analysis of IgG by systems serology has identified that humoral features in patients with MIS-C, such as complement deposition and neutrophil phagocytosis, overlap with those in convalescent adults with COVID-19. However, patients with severe MIS-C have persistent levels of FcyR binding (and in particular activating FcyRIIA) and inflammatory monocyte/macrophage-activating IgG. Although hypergammaglobulinaemia is not observed in patients with MIS-C, a selective expansion of the IgG repertoire to react not only to SARS-CoV-2, but also to other bacterial and viral pathogens, some of which are implicated in the triggering of Kawasaki disease, has been observed. The underlying reason for the enrichment of particular IgG specificities is not yet known, but many of the microbes that have been identified in the respiratory tracts of patients with MIS-C, suggesting a role for an immune-complex-driven inflammatory response in the pathogenesis of MIS-C. IgG and IgA autoantibodies occur in patients with MIS-C, and recognize gastrointestinal, mucosal, immune-cell and endothelial antigens. Although the functionality of these autoantibodies and their roles in the pathogenesis of MIS-C should be investigated, these results might explain at least in part the involvement of multiple organ systems in MIS-C and provide a pointer towards dysregulation of B lymphocytes, enhanced autoreactivity and immune-complex-mediated inflammatory responses. Enhanced expression of CD64 (FcyR1), a high-affinity receptor for the Fc fragment of IgG, has been observed on neutrophils and monocytes of patients with MIS-C. Furthermore, most of these patients respond to IVIG therapy, which provides additional indirect support for the implication of FcyR-mediated activation of innate immune cells by immune complexes formed by these IgGs.

A role for the complement system in the pathogenesis of MIS-C has been suggested. Patients with MIS-C or paediatric COVID-19 have elevated plasma levels of soluble C5b-9 compared with healthy controls. Soluble C5b-9 is a biomarker to monitor the activity of the terminal pathway of complement, and elevated levels suggest complement activation and endothelial dysfunction. Notably, although patients with MIS-C and paediatric COVID-19 have similar levels of complement-activating IgG antibodies to S protein of SARS-CoV-2, those with MIS-C have enhanced autoreactive signatures of IgG. As patients with MIS-C typically have minimal or no SARS-CoV-2 at the time of development of the disease, enhanced autoreactivity and immune-complex formation might contribute to the elevated levels of C5b-9. Consistent with complement activation, MIS-C is associated with clinical criteria for complement-mediated thrombotic microangiopathy, such as microangiopathic haemolytic anaemia, hypertension, thrombocytopenia, proteinuria and evidence of organ damage on the basis of lactate dehydrogenase elevation. Compared with paediatric COVID-19, patients with MIS-C have higher incidence of thrombotic events. Results from proteomics analyses of plasma samples, which have not yet been peer reviewed, suggest that phospholipase A2 (PLA2G2A) could be a biomarker for diagnosis of thrombotic
microangiopathy in MIS-C. The lectin complement pathway might also have an important role in the pathogenesis of diseases associated with SARS-CoV-2, as a result of the carbohydrate-residue-rich surface structures of the virus.

**Therapeutic strategies**

Treatment approaches to MIS-C aim to mute the exaggerated inflammatory response. Multiple approaches, borrowed from Kawasaki disease and other hyperinflammatory syndromes, have been considered, ranging from IVIG to glucocorticoids and immunotherapy. MIS-C treatment regimens described in 24 studies, involving 1,020 individuals, are summarized in Table 3, highlighting the many variations on the theme of attempting to calm overactive inflammatory responses. In most studies, most (70–100%) of the patients were treated with IVIG as the first-line agent, with satisfactory results. Steroids were the second most common treatment employed for patients with MIS-C.

Shock and cardiovascular manifestations comprise a predominant mode of presentation of MIS-C, and high-dose glucocorticoids have been advocated for, and used successfully in, patients with shock. Widely followed guidance from the ACR recommends IVIG as first-line therapy in hospitalized patients with MIS-C, with addition of glucocorticoids in the presence of shock, organ-threatening disease or refractory disease.

In a study of 181 children with suspected MIS-C, IVIG alone had a higher failure rate than the use of IVIG with methylprednisolone (OR 0.25; 95% CI 0.09–0.70). By contrast, results from a multinational observational cohort study that involved 615 children with suspected MIS-C identified no difference in acute outcomes between primary treatment with IVIG alone, IVIG with steroids or steroids alone. In view of the apparently important role of IL-1β in the pathogenesis of MIS-C, anakinra (an IL-1 receptor antagonist) has been used in MIS-C that is refractory to therapy with IVIG or steroids, extrapolating from its success in small groups of patients with IVIG-resistant Kawasaki disease.

Zonulin-dependent loss of intestinal mucosal permeability is implicated in mediation of the hyperinflammation observed in MIS-C, and accordingly, a patient who did not respond to anti-inflammatory therapies

### Table 3: Treatment of MIS-C

| Study | Cohort location | N  | IVIG (%) | Glucocorticoids (%) | Other treatments | Ref. |
|-------|----------------|----|----------|---------------------|------------------|------|
| Dufort et al. | USA | 99 | 70 | 64 | NR | 14 |
| Cheung et al. | USA | 17 | 77 | 82 | Tocilizumab, 6% | 15 |
| Belhadjer et al. | France, Switzerland | 35 | 72 | 34 | Anakinra, 9% | 122 |
| Kaushik et al. | USA | 33 | 54 | 51 | Tocilizumab, 36%; remdesivir, 21%; anakinra, 12%; convalescent plasma therapy, 3% | 125 |
| Davies et al. | UK | 78 | 76 | 73 | Tocilizumab, 4%; anakinra, 10%; infliximab, 9%; rituximab, 1% | 126 |
| Pouletty et al. | France | 16 | 94 | 18.8 | Tocilizumab, 6%; anakinra, 6%; hydroxychloroquine, 6% | 127 |
| Toubiana et al. | France | 21 | 100 | 33 | NR | 128 |
| Capone et al. | USA | 33 | 100 | 70 | Tocilizumab, 9%; anakinra, 12%; infliximab, 3% | 129 |
| Hameed et al. | UK | 35 | 100 | 100 | NR | 130 |
| Whittaker et al. | UK | 58 | 71 | 64 | Anakinra, 5%; infliximab, 14% | 131 |
| Moraleda et al. | Spain | 31 | 65 | 68 | Remdesivir, 6% | 132 |
| Dhanalakshmi et al. | India | 19 | 79 | 58 | Tocilizumab, 5% | 133 |
| Miller et al. | USA | 44 | 82 | 96 | Anakinra, 18% | 134 |
| Lee et al. | USA | 28 | 71 | 61 | Anakinra, 18% | 135 |
| Riollano-Cruz et al. | USA | 15 | 80 | 20 | Tocilizumab, 80%; remdesivir, 13%; anakinra, 13%; convalescent plasma therapy, 6% | 136 |
| Ramcharan et al. | UK | 15 | 66 | 33 | NR | 137 |
| Grimaud et al. | France | 20 | 100 | 10 | Tocilizumab, 10%; anakinra, 10% | 138 |
| Jonat et al. | USA | 54 | 83 | 79 | NR | 139 |
| Feldstein et al. | USA | 186 | 77 | 49 | Anakinra, 13% | 140 |
| Toubiana et al. | France | 23 | 100 | 61 | NR | 141 |
| Garcia-Salido et al. | Spain | 61 | 45 | 80 | Tocilizumab, 24%; hydroxychloroquine, 55% | 142 |
| Shobhavat et al. | India | 21 | 52 | 86 | Tocilizumab, 10% | 143 |
| Niño-Taravilla et al. | Chile | 26 | 77 | 88 | Tocilizumab, 12%; infliximab, 4% | 144 |
| Tolunay et al. | Turkey | 52 | 93 | 71 | Anakinra, 4% | 145 |

IVIG, intravenous immunoglobulin; MIS-C, multisystem inflammatory syndrome in children; NR, not reported.
was treated with the zonulin antagonist larazotide, with a satisfactory outcome. In a pooled meta-analysis, D-dimer was found to be elevated in 92% of patients (330 out of 356). Because of the associated risk of hypercoagulability, and extrapolating from the management of Kawasaki disease, the use of anticoagulants such as acetylsalicylic acid and/or enoxaparin has been reported.

**MIS-C: distinct from Kawasaki disease?**

Both Kawasaki disease and MIS-C have temporal associations with infectious diseases and are associated with immune-system alteration, systemic inflammation and cytokine storm. Myocardial dysfunction, which is seen in both pathologies, might be a consequence of systemic inflammation. An artificial intelligence computational analysis based on viral pandemics and disease-severity gene signatures, and in particular induction of IL15--IL15RA genes, has placed Kawasaki disease and MIS-C on the same host-immune-response continuum (although these results have not yet been peer reviewed). Consistently, patients with MIS-C have significantly higher levels of IL-15 than paediatric patients with COVID-19. However, the intensity of the immune response is high in MIS-C, which places it further along the severity spectrum than Kawasaki disease.

A quarter to half of patients with MIS-C meet the full criteria for diagnosis of Kawasaki disease. Without evidence of prior SARS-CoV-2 exposure in these patients, it might not be possible to differentiate them from those with classic Kawasaki disease. Commonly reported clinical features of MIS-C include fever, mucocutaneous findings, myocardial dysfunction with cardiogenic or vasoplegic shock, gastrointestinal symptoms and neurological features including headache and altered mental status. Like Kawasaki disease, these clinical manifestations are not specific to MIS-C, and they could occur in other infectious or inflammatory conditions.

**Epidemiological and clinical differences**

Despite the apparent similarities between MIS-C and Kawasaki disease, there are important epidemiological and clinical differences. Kawasaki disease is typically a disease of young children <5 years old, whereas MIS-C has been reported in a wide age range from 1.6 to 20 years, with a median age of 6–11 years. Without evidence of prior SARS-CoV-2 exposure in these patients, it might not be possible to differentiate them from those with classic Kawasaki disease. Commonly reported clinical features of MIS-C include fever, mucocutaneous findings, myocardial dysfunction with cardiogenic or vasoplegic shock, gastrointestinal symptoms and neurological features including headache and altered mental status. Like Kawasaki disease, these clinical manifestations are not specific to MIS-C, and they could occur in other infectious or inflammatory conditions.

Fewer than 10% of cases of Kawasaki disease manifest as Kawasaki disease-shock syndrome (KDSS), which requires the use of intravascular fluid resuscitation and vasoactive medication. Patients with KDSS tend to be older, have longer duration of fever and higher levels of inflammatory markers, and have a higher incidence of IVIG resistance as well as coronary abnormalities than those without KDSS. By contrast, shock and depressed left ventricular systolic function are more frequent with MIS-C, for which reports indicate that 40–80% of patients present with shock. In a retrospective comparison of a cohort of patients with KDSS with published data relating to MIS-C, individuals with KDSS were more likely than those with MIS-C to fulfil the diagnostic criteria for complete Kawasaki disease, with higher incidence of coronary artery aneurysms.

Kawasaki disease has been reported to occur with MAS. In a retrospective analysis of 638 patients with Kawasaki disease, the incidence of MAS was <2%. However, this figure is likely to be an underestimation of the true incidence, as a result of an absence of sensitive diagnostic criteria and a lack of awareness among health-care providers. Patients with Kawasaki disease and MAS tend to have elevation of levels of IFNγ, TNF, serum neopterin, IL-18 and sTNFR-II. A retrospective comparison of patients with MAS (as a complication of systemic-onset juvenile idiopathic arthritis) and MIS-C revealed that MAS was associated with lower levels of haemoglobin and fibrinogen, and higher ferritin and lactate dehydrogenase, whereas patients with MIS-C tended to have signs of shock and need of intensive care management. Results that have not yet been peer reviewed, based on analyses of IFNγ and CXCL9 signalling characteristics, suggest that >50% of patients with MIS-C have a MAS-like cytokine phenotype, along with elevation of CD163, IL-2RA and ferritin (during the early period) in the plasma. However, although MAS has an association with neutropenia, patients with MIS-C, including those who meet the criteria for MAS, display neutrophilia. Thus, although KDSS and Kawasaki disease with MAS have overlapping clinical features with MIS-C, there are subtle differences that are likely to reflect the different cytokine profiles in these conditions.
Gastrointestinal and neurological symptoms are also more commonly encountered in MIS-C than in Kawasaki disease\textsuperscript{134,235,236,244–247}. The gastrointestinal manifestations include abdominal pain, vomiting and diarrhoea\textsuperscript{210,235,246}, with rare presentations that resemble appendicitis requiring surgical exploration\textsuperscript{248}. In a national US registry consisting of 1,695 children and adolescents with active COVID-19 infections including

| Affected organ system | Symptoms | Frequency of involvement (%) | Refs |
|-----------------------|----------|------------------------------|------|
| Cardiovascular        | Shock    | 40–80                        | 210,234–235 |
|                       | Cardiac arrhythmias | 2 | 235 |
|                       | Abnormal ST- or T-wave segment | 22 | 235 |
|                       | Prolonged QT interval | 2 | 235 |
|                       | Pericardial effusion | 13–28 | 235,248 |
|                       | Decreased LVEF by echo | 31–58 | 234,235 |
|                       | Increased troponin | 68–95 | 234,235 |
|                       | Myocarditis | 36–87 | 210,235,236,246 |
|                       | Coronary artery dilation on CT | 27 | 235 |
|                       | Coronary artery aneurysm | 14–48 | 234–239 |
|                       | Mild | 2 | 235 |
|                       | Moderate | 7 | 235 |
|                       | Giant | 1 | 235 |
| Gastrointestinal      | Gastrointestinal symptoms | 60–100 | 234–239 |
|                       | Diarrhoea | 38–72 | 210,235 |
|                       | Vomiting | 51–68 | 210,235 |
|                       | Abdominal pain | 19–71 | 210,235 |
|                       | Ascites | 21 | 235 |
|                       | Ileitis | 9 | 235 |
|                       | Colitis | 4 | 235 |
| Ophthalmological      | Conjunctivitis | 32–83 | 234–238,248,254 |
|                       | Periorbital erythema and oedema | 20 | 264 |
| Nervous system        | Neurological symptoms | 13–35 | 230,235,236,246,249 |
|                       | Severe symptoms, including encephalopathy, stroke, central nervous system infection/demyelination, Guillain–Barré syndrome and acute cerebral oedema | 3 | 249 |
| Integumentary         | Rash | 50–70 | 234,235,236,238,246,249 |
|                       | Erythematous skin rash | 62 | 235 |
|                       | Hyperaemia, oedema or desquamation of extremities | 26–51 | 235,236,246 |
|                       | Malar erythema | 17 | 264 |
|                       | Skin eruptions | 9–14 | 264 |
|                       | Desquamation in groin | 26 | 239 |
| Respiratory           | Upper respiratory tract infection | 34 | 235 |
|                       | Lower respiratory tract infection | 22 | 235 |
|                       | Pleural effusion on CT | 20 | 235 |
|                       | Lung involvement on CT (bilateral pulmonary consolidation and ground-glass opacity) | 13 | 235 |
| Mucosal               | Oral mucosa hyperaemia | 41 | 235 |
|                       | Red and/or cracked lips | 37–49 | 248,254 |
|                       | Strawberry tongue | 11–23 | 248,254 |
|                       | Lips and oral-cavity changes | 74 | 235 |
| Other                 | Lymphadenopathy (cervical) | 19–61 | 235,236,238,246 |
|                       | Extremity changes | 8–52 | 235,236,238,246 |

LVEF, left ventricular ejection fraction.
Coronary artery dilation or aneurysm from published reports210,231,232,234–236,246,249,250,264–270. Although some clinical signs, such as syndrome in children (MIS-C) or Kawasaki disease is shown, with the values derived Percentage incidence of particular symptoms in patients with multisystem inflammatory disease, the incidence of other symptoms, including shock, coronary artery involvement and gastrointestinal symptoms (vomiting, diarrhoea or abdominal pain), are characteristic of MIS-C. a’Conjunctival injection’ refers to bilateral non-exudative conjunctivitis in Kawasaki disease. b’Rash’ refers to polymorphous rash in Kawasaki disease. c’Coronary artery dilation or aneurysm’ refers to untreated cases of Kawasaki disease.

Fig. 3 | Comparative incidence of clinical signs in MIS-C and Kawasaki disease. Percentage incidence of particular symptoms in patients with multisystem inflammatory syndrome in children (MIS-C) or Kawasaki disease is shown, with the values derived from published reports210,231,232,234–236,246,249,250,264–270. Although some clinical signs, such as fever and cervical lymphadenopathy are equally prevalent in both MIS-C and Kawasaki disease, the incidence of other symptoms, including shock, coronary artery involvement and gastrointestinal symptoms (vomiting, diarrhoea or abdominal pain), are characteristic of MIS-C. a’Conjunctival injection’ refers to bilateral non-exudative conjunctivitis in Kawasaki disease. b’Rash’ refers to polymorphous rash in Kawasaki disease. c’Coronary artery dilation or aneurysm’ refers to untreated cases of Kawasaki disease.

In a study evaluating 29 children with MIS-C and Kawasaki disease, with superantigen-mediated activation of the immune system is lacking50.

Autoantibody profiles have been compared in patients with MIS-C and Kawasaki disease165. Levels of antibodies to some vascular endothelial cell proteins, such as endoglin, were higher in both groups of patients than in healthy controls, whereas some autoantibodies (such as to EGF-like repeat and discoidin I-like domain-containing protein 3) were overexpressed in Kawasaki disease compared with MIS-C103. Levels of Vβ 21.3’ T cell subset expansion noted in MIS-C is consistent with superantigen-mediated activation of the immune system11, whereas in Kawasaki disease, evidence of a role of superantigens in pathogenesis is lacking46.

In a study of the immunological profiles of paediatric patients, 75% of those with MIS-C, but none with Kawasaki disease, TSS or COVID-19, displayed non-HLA-biased, SARS-CoV-2 non-reactive, polyclonal expansion of TCR Vβ 21.3’ activated CD4+ and CD8+ T cells46. Notably, these Vβ 21.3’ T cells had high expression of CX3CR1, a marker previously identified on the activated CD8+ T cells of patients with MIS-C46. The remarkable specificity of Vβ 21.3’ T cell subset expansion noted in MIS-C is consistent with superantigen-mediated activation of the immune system11, whereas in Kawasaki disease, evidence of a role of superantigens in pathogenesis is lacking46.

Autoantibody profiles have been compared in patients with MIS-C and Kawasaki disease165. Levels of antibodies to some vascular endothelial cell proteins, such as endoglin, were higher in both groups of patients than in healthy controls, whereas some autoantibodies (such as to EGF-like repeat and discoidin I-like domain-containing protein 3) were overexpressed in Kawasaki disease compared with MIS-C. To confound matters, plasma levels of endoglin were elevated in both sets of patients compared with healthy children, raising the possibility that antibodies to endothelial cells were the result, rather than the cause, of vascular damage. Another possibility is that the S protein superantigen of SARS-CoV-2 might cause aberrant activation of B cells46.

Some laboratory parameters are important differentiators between Kawasaki disease and MIS-C. Although both syndromes involve a diffuse hyperinflammatory response, patients with MIS-C tend to have a lower platelet count, lower absolute lymphocyte count and higher levels of C-reactive protein, N-terminal pro-B-type natriuretic peptide, troponin and ferritin166. Additionally, coagulation abnormalities are common, including elevation of D-dimer and fibrinogen levels. Hyponatraemia is another common laboratory finding in patients with MIS-C103. The presence markers, troponin, B-type natriuretic peptide and D-dimer levels also identified patents at risk of severe disease206. In a study evaluating 29 children with MIS-C in France, severe disease occurred in 52% of them and was associated with high persistent fever and high levels of inflammatory markers205. Although the reason for a more critical illness in the acute phase of MIS-C than in Kawasaki disease is unclear, it is thought to be linked to the cytokine storm in MIS-C216,257.
of burr cells and neutrophils with toxic granulation can also discriminate MIS-C from severe COVID-19 (REF. 19). Finally, evidence of recent SARS-CoV-2 infection, particularly by positive serology, is a diagnostic indicator of MIS-C16,18.

Conclusion

Epidemiological and clinical differences reveal that although MIS-C has phenotypic similarities to Kawasaki disease, they are different syndromes. They have varying degrees of hyperinflammation and dysregulated immune responses13. Children with MIS-C are, in general, more critically ill, with prominent gastrointestinal symptoms, cardiac involvement with shock, haematological abnormalities and elevated acute-phase reactants. They have positive SARS-CoV-2 serology, suggesting a link to prior clinical or subclinical infection or exposure. It is likely that a combination of pathogen and host factors is involved in the genesis of an intense aberrant activation of both innate and adaptive immune responses and subsequent cytokine storm14,15. Some of the pathogen-related factors include antigen mimicry of host antigens, and superantigen properties of viral proteins. Potential host factors include age and immune-system immaturity, altered intestinal microbiota, nutritional deficiencies and genetic (including inborn errors of immunity) and epigenetic predisposition1. However, to what extent each of these factors contributes, and how they interact to cause the clinical syndrome, are relative unknowns that need further exploration. Various lines of evidence based on inflammatory parameters, clinical signs or gene analyses have evoked the possibility that MIS-C is a heterogeneous complex disorder. Current data on the immune signatures in patients with MIS-C are based on small sample size, non-homogeneous cohorts. Hence, analysis of dynamic changes in the immune signatures of patients with MIS-C and their comparison with those with Kawasaki disease in a large homogeneous cohort is needed, to accurately determine the similarities and distinct features of the two disease entities. Nevertheless, with the evidence of elevation of signatures of autoimmunity in MIS-C, and reports of various post-COVID-19 conditions in adults, long-term follow-up of patients with MIS-C might be advisable, because of the possibility of relapse. Notably, however, relapse is rare in Kawasaki disease, which might suggest that recurrence is also unlikely in MIS-C.

While researchers and clinicians navigate the possibilities and evaluate the best treatment options for patients affected by COVID-19-related illnesses, it is imperative to establish registries and dedicated multidisciplinary research teams to investigate the pathogenesis and specific therapeutic strategies in MIS-C. An important step towards this end was the workshop that was convened by the NIH in June 2020, which aimed to bring together the experts on the subject, to initiate dialogue leading to future studies19. In conclusion, MIS-C has important epidemiological, clinical and immunological differences from Kawasaki disease, enabling its classification as a separate syndrome. Study of MIS-C will continue to enhance our understanding of these conditions that are related by their association with the cytokine storm phenomenon.

Published online 29 October 2021

1. Lai, C.-C. et al. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int. J. Antimicrob. Agents 55, 105946 (2020).
2. Cucinotta, D. & Vanelli, M. WHO declares COVID-19 a pandemic. Acta Bio Med. Atenei Parm. 91, 157–160 (2020).
3. Bickels, B. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. JACC 75, 2950–2973 (2020).
4. Montalvan, V., Lee, J., Busno, T., De Toledo, J. & Rivas, K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin. Neurol. Neurosurg. 194, 105921 (2020).
5. Clerkin, K. et al. COVID-19 and cardiovascular disease. Circulation 141, 1646–1655 (2020).
6. Hoffman, J. I. & Kaplan, S. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 39, 1890–1900 (2002).
7. Copencini, F., Chiocchi, G., Croce, L., Magri, F. & Rotondi, M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 55, 25–52 (2020).
8. Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).
9. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 e8 (2020).
10. Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. ElbioMedicine 55, 102763 (2020).
11. Verdrus, L. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 395, 1771–1778 (2020).
12. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
13. Riphagen, S., Gomez, Y., Gonzalez-Martinez, C., Wilkinson, N. & Thesfaharis. P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395, 1607–1608 (2020).
14. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
15. Feldstein, L. R. et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 383, 354–364 (2020).
16. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
17. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
18. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
19. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
20. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
21. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
22. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
23. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
24. Cheung, E. W. et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 324, 294–296 (2020).
25. An early report of MIS-C from the first wave of COVID-19 in mid-2020.
26. Gallagher, C. & Bayry, J. Autoimmune and inflammatory diseases following COVID-19. Nat. Rev. Rheumatol. 16, 413–414 (2020).
27. Simpson, J. M. & Newburger, J. W. Multi-system inflammatory syndrome in children in association with COVID-19. Circulation 142, 437–440 (2020).
28. Levin, M. Childhood multisystem inflammatory syndrome — a new challenge in the pandemic. N. Engl. J. Med. 383, 393–395 (2020).
29. Kawasaki, T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Amer. J. Dis. Child. 166, 178–122 (1967).
30. McCrindle Brian, W. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135, e927–e99 (2017).
31. Burns, J. C. et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J. Infect. Dis. 192, 544–546 (2005).
32. Burgner, D. et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet. 5, e1000319 (2009).
33. Burgner, D. & Harnden, A. Kawasaki disease: what is the epidemiology telling us about the etiology? Int. J. Infect. Dis. 9, 185–194 (2005).
34. Son, M. B. F. & Newburger, J. W. Kawasaki disease. Pediatr. Rev. 39, 78–90 (2018).
35. Burrs, J. C. The riddle of Kawasaki disease. N. Engl. J. Med. 356, 659–661 (2007).
36. Holman, R. C., Burns, A. T., Bayley, E. D., Steiner, C. A. & Schonberger, L. B. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 112, 495–501 (2003).
37. Kuipers, T. W. et al. Kawasaki disease: a maturational defect in immune responsiveness. J. Infect. Dis. 180, 1869–1877 (1999).
38. Green, M. S. The male predominance in the incidence of infectious diseases in children: a postulated explanation for disparities in the literature. Int. J. Epidemiol. 21, 581–586 (1992).
39. Burgner, D. & Levin, M. Genetic susceptibility to infectious diseases. Pediatr. Infect. Dis. J. 22, 1–6 (2003).
40. Harnden, A., Alves, B. & Sheikh, A. Rising incidence of Kawasaki disease in the United States, 1997 and 2000. Int. J. Epidemiol. 26, 381–386 (1997).
41. Burgner, D. & Levin, M. Genetic susceptibility to infectious diseases. Pediatr. Infect. Dis. J. 22, 1–6 (2003).
42. Harnden, A., Alves, B. & Sheikh, A. Rising incidence of Kawasaki disease in the United States, 1997 and 2000. Int. J. Epidemiol. 26, 381–386 (1997).
The covid-19 pandemic in Paris, France: prospective observational study. BMJ 369, m2094 (2020).
An early report of MIS-C from the first wave of COVID-19 in mid-2020

Guidelines article on the management of MIS-C

A report on the implication of zoonotic-dependent loss of intestinal mucosal permeability in the pathogenesis of MIS-C and the therapeutic application of zonulin antagonist laraizinotide.

Bartsch, Y. et al. Humoral signatures of protective and pathologic SARS-CoV-2 infection in children. Nat. Med. 27, 454–462 (2020).

This article reports that children with MIS-C maintain FcγR-binding, inflammatory monocye/macrophage-activating SARS-CoV-2 IgG antibodies.

Marques, J. et al. SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89–94 (2020).

Grillo, A. et al. Targeted T cell responses to SARS-CoV-2 in coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1469–1501.e15 (2020).

Sermet-Gaudelus, I. et al. Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children. France, April to June 2020. Eur. Surveill. 26, 2001782 (2021).

Rivas, M. N., Porritt, R. A., Cheng, M. H., Bahar, I. & Ardi, M. COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): a novel disease that mimics toxic shock syndrome—the superantigen hypothesis. J. Allergy Clin. Immunol. 147, 57–59 (2021).

Cheng, M. H. et al. Superantigenic character of an insert unique to SARS-CoV-2 proteins as supported by skewer TCR repertoire in patients with hyperinflammation. Proc. Natl Acad. Sci. USA 117, 25254–25262 (2020).

Evidence that SARS-CoV-2 spike protein acts as a superantigen leading to HLA class I-associated expansion of TRBV11-2 T cells in MIS-C

Porritt, R. A. et al. HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J. Clin. Invest. 131, e16641 (2021).

Evidence that SARS-CoV-2 spike protein acts as a superantigen leading to an HLA class I-associated expansion of TRBV11-2 T cells in MIS-C

Moreno, M. et al. Polyclonal expansion of TCR Vγ 224.3 CD4⁺ and CD8⁺ T cells is a hallmark of
multisystem inflammatory syndrome in children. Sci. Immunol. 6, eabf1516 (2021).

Patients with MIS-C present a unique CD4+ and CDB− T cell TCR repertoire with a polyclonal expansion of CD8+ T cells expressing activated (TRBV11-2)/VJ2.13 clonotype.

McCormick, J. K., Yanwood, J. M. & Schlevert, P. M. Toxic shock syndrome: bacterial superantigens and an update. Annu. Rev. Microbiol. 55, 77–104 (2001).

Raduikova, A. et al. Vitamin D deficiency and outcome in COVID-19 patients. J. Inflamm. 17, 27 (2020).

Urashima, M. et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 91, 1255–1260 (2015).

Omenetti, S. & Pizarro, T. The Treg/TH17 axis: a therapeutic target for rheumatic diseases. Front. Immunol. 6, 2250512 (2015).

Yeo, Y. K. et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 70, 698–706 (2021).

Zuo, T. et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. Gastroenterology 159, 1302–1510.e5 (2020).

I. M. J. Carter et al. Peripheral immunophenotypes in children with MIS-C associated with SARS-CoV-2 infection. Sci. Immunol. 6, eabf5687 (2020).

Caldarale, F. et al. Plasmacytoid dendritic cells depletion and dependent chemokines CXCL9 and CXCL10 in children with multisystem inflammatory syndrome. Front. Immunol. 12, 654887 (2021).

Pearl Akindede, N. et al. Distinct cytokine and chemokine dysregulation in hospitalized children with acute COVID-19 and multisystem inflammatory syndrome with similar levels of nasopharyngeal SARS-CoV-2 shedding. J. Infect. Dis. 224, 606–615 (2021).

Dorio, C. et al. Proteomic profiling of MIS-C patients reveals heterogeneity of interferon-gamma dysregulation and vascular endothelial dysfunction. Preprint at medRxiv https://www.medrxiv.org/ content/10.1101/2021.04.13.21255439v1 (2021).

Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. JID Insight 5, e158999 (2020).

Middelton, E. A. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169–1179 (2020).

Yamashita, K., Takakori, K., A. Mizugushi, K. Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the onset of thrombotic microangiopathy. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2020-218593 (2020).

Seier, V. et al. Blood neutrophils from children with COVID-19 exhibit both inflammatory and anti-inflammatory markers. ElBioMedicine 67, 103357 (2021).

Beckmann, N. D. et al. Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nat. Commun. 12, 4854 (2021).

Vojdani, A., Vojdani, E. & Kharrazian, D. Reaction of pro-inflammatory cytokines in patients with life-threatening COVID-19. JAMA Pediatr. 22, e21255439v1 (2021).

Sahin, U. et al. An unlicensed signature places MIS-C with Kawasaki disease in a continuum of host immune responses. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2020.11.11.349547v2 (2021).

Newburger, J. W. et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 324, 1633–1639 (1991).

Abra, J. Y. et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. J. Pediatr. 226, 45–54.e1 (2020).

Ouldilni, N. et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicenter of the French COVID-19 epidemic: a time-series analysis. Lancet Child. Adolesc. Health 4, 662–668 (2020).

Choe, Y. J. et al. Surveillance of COVID-19-associated multisystem inflammatory syndrome in children, South Korea. Emerg. Infect. Dis. 27, 1196–1200 (2021).

Li, W., Tang, Y., Shi, Y., Chen, Y. & Liu, E. Why multisystem inflammatory syndrome in children has been less described in Asia? Transl. Pediatr. 9, 875–875 (2020).

B. S. M. et al. Treatment of Kawasaki disease: analysis of 27 US pediatric outbreaks from 2001 to 2006. Pediatrics 124, 1–8 (2009).

Coom, E. R., Wilkes, J., Bratton, S. L. & Srivastava, R. Paediatric overdiagnosis modelled by coronary artery abnormalities in Kawasaki disease. Arch. Dis. Child. 103, 937–941 (2018).

Ghatani, S., Kiwata, M. & Spurrey, C. F. Can coronary artery involvement in Kawasaki disease be predicted? Diagnostics 5, 243–253 (2015).

Gong, G. W. K., McInride, B. W., Ching, J. C. & Yung, R. S. M. Arthritis presenting during the acute phase of Kawasaki disease. J. Pediatr. 148, 800–805 (2006).

Blondua, E. et al. Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19. Radiother. 297, E283–E288 (2020).

Gaitonde, M. et al. Characterization of multisystem inflammatory syndrome in children affects left ventricular function and global strain compared with Kawasaki disease. J. Am. Soc. Echocardiogr. 33, 1285–1287 (2020).

Jhaveri, S. et al. Longitudinal echocardiographic assessment of coronary arteries and left ventricular function following multisystem inflammatory syndrome in children. J. Pediatr. 228, 290–295 (2020).

Gonzalez-Gonzalez, L. B. et al. Kawasaki disease: unique and novel presentations of Kawasaki disease. Pediatr. Int. 60, 781–790 (2018).

Tuca, E. et al. Changes in causes of sudden deaths by cardiovascular diseases among adult men and women in Turkey from 1973 to 2018. Cardio. Young. 15, 481–488 (2005).

Gatterre, P. et al. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med. 38, 872–878 (2012).
